ArticleTherapeutic drug monitoring2026
A Real-World Clinical Evaluation of Ganciclovir Exposure and Cytomegalovirus Viremia Outcomes After Adult Kidney Transplantation.
Article in Therapeutic drug monitoring, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe efficacy and toxicity of valganciclovir prophylaxis are determined by ganciclovir (GCV) exposure. As GCV is predominantly eliminated through glomerular filtration, kidney transplant recipients are at risk of both under- and overexposure. Kidney function is dynamic and GCV exposure may be off-target shortly after kidney transplantation and in kidney transplant recipients with delayed graft function (DGF). However, the extent of GCV under- and overexposure in the early phase after kidney transplantation has not been well described.
methodsThis was a retrospective, single-center analysis of adult patients who received valganciclovir prophylaxis and underwent at least one predose steady-state GCV concentration measurement during the first month after kidney transplantation. Data on GCV measurements, target attainment, and clinical outcomes, including cytomegalovirus (CMV) viremia and leukopenia, were collected and analyzed.
resultsOverall, 353 patients were included, with 357 predose and steady-state GCV concentration measurements. GCV exposure was highly variable early after kidney transplantation, especially in patients with poorly functioning grafts and those undergoing dialysis. Overall, there was a large proportion of patients with GCV exposure below the target, especially those with higher estimated kidney function, despite many receiving high GCV dosages. However, despite the frequent occurrence of off-target GCV exposure, no association was observed between DGF, GCV exposure, and CMV viremia.
conclusionsIn the early phase after kidney transplantation, exposure to GCV is highly variable among patients and underexposure to GCV occurs frequently. However, DGF was not associated with reduced exposure to GCV or CMV viremia, nor was early exposure to GCV correlated with CMV outcomes or leukopenia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.